|Vital therapies … Professor Ian Chubb with
ACN Co-Director Professor Justin Gooding
Professor Chubb said work like the ACN’s was central to the purpose of Australia’s universities.
“The purpose of universities is to use our talents to make the world a better place,” Professor Chubb said.
“Nanomedicine will enable better delivery of drugs and vital therapies to individuals who would not prosper without that treatment.”
The ACN, in partnership with the Children’s Cancer Institute Australia (CCIA) and UNSW’s Lowy Cancer Research Centre, is targeting neuroblastoma among its initial projects. Neuroblastoma is a difficult-to-treat cancer – the most common tumour in children under five years of age and one which has one of the lowest survival rates – 40 to 50 per cent.
|Target … lung cancer cells showing
penetration by gene-silencing
nanoparticles (in green)
Professor Kavallaris said the centre was investigating the use of organic nanoparticles to deliver gene-silencing therapy to the site of the cancer.
“Using nanomedicine we work with engineers and chemists to custom-design the vehicles that will deliver a treatment direct to the site of the disease. This technique may also allow us to use less of the drug and minimise harmful side effects,” Professor Kavallaris said.
The ACN is also developing treatments for lung cancer and chronic liver disease, and investigating new pain management drugs derived from marine life among its initial projects.
Nanomedicine uses the changed properties of materials at the nanometre scale – measured in millionths of a millimetre – to develop revolutionary drug delivery, gene therapy, cell regeneration and disease diagnosis methods not possible in conventional medicine.
The multidisciplinary ACN comprises researchers from the UNSW Faculties of Medicine, Science and Engineering, the CCIA and the UNSW Centre for Advanced Macromolecular Design.